Methylthioadenosine phosphorylase

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

MTAP

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Phosphorylase which plays an essential role in the polyamine metabolism and thus for the utilization of adenine and methionine. Methylthioadenosine phosphorylase (MTAP) catalyses the phosphorylation of methyl adenosine (MTA), which acts as a potent inhibitor of methyl transferases. MTAP is expressed in most cells and tissues and is considered a "household enzyme" in its function. The encoding gene is located in close proximity to numerous tumour suppressor genes (p15, p16, p14ARF) on chromosome 9p21.

OccurrenceThis section has been translated automatically.

In malignant melanomas a loss of MTAP expression has been demonstrated in vitro as well as in vivo, which in most cases is caused by a strongly decreased expression of promoter methylation (both on mRNA level and protein level). In malignant melanoma this deficiency has an influence on the invasive potential of the tumour cell. In addition, a downregulation of MTAP seems to lead to interferon resistance, so that such patients may not benefit from interferon therapy.

LiteratureThis section has been translated automatically.

  1. Wild PJ et al (2007) Methylthioadenosine phosphorylase (MATP): Potential marker for a response to interferon therapy in malignant melanoma. JDDG 6: 456-459

Authors

Last updated on: 29.10.2020